Gilead Sciences’ (GILD) Market Perform Rating Reiterated at Leerink Swann
Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “market perform” rating reaffirmed by equities researchers at Leerink Swann in a report released on Wednesday. They currently have a $87.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $82.00. Leerink Swann’s price target would indicate a potential upside of 5.72% from the stock’s current price.
GILD has been the topic of several other research reports. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Morgan Stanley reiterated an “equal weight” rating on shares of Gilead Sciences in a research note on Tuesday, July 11th. Royal Bank Of Canada started coverage on shares of Gilead Sciences in a research note on Thursday, September 14th. They set an “outperform” rating and a $94.00 price objective on the stock. Robert W. Baird reiterated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Berenberg Bank set a $86.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, August 29th. Eleven equities research analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $84.29.
Gilead Sciences (NASDAQ:GILD) traded down 0.15% during mid-day trading on Wednesday, hitting $82.17. The stock had a trading volume of 3,218,059 shares. The company has a 50 day moving average price of $77.54 and a 200 day moving average price of $70.38. Gilead Sciences has a one year low of $63.76 and a one year high of $86.27. The stock has a market cap of $107.31 billion, a P/E ratio of 8.92 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion for the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.08 earnings per share. On average, equities analysts anticipate that Gilead Sciences will post $8.78 EPS for the current year.
WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/gilead-sciences-gild-market-perform-rating-reiterated-at-leerink-swann/1576314.html.
In other Gilead Sciences news, CFO Robin L. Washington sold 51,820 shares of the stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the sale, the chief financial officer now owns 43,352 shares in the company, valued at approximately $3,684,920. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $83.05, for a total transaction of $2,076,250.00. Following the completion of the sale, the executive vice president now owns 101,488 shares of the company’s stock, valued at approximately $8,428,578.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 466,819 shares of company stock valued at $36,740,240. Insiders own 1.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Gilead Sciences by 583.3% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its holdings in shares of Gilead Sciences by 19.4% during the 1st quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 267 shares in the last quarter. Penserra Capital Management LLC raised its holdings in shares of Gilead Sciences by 9.5% during the 1st quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares in the last quarter. Webster Bank N. A. raised its holdings in shares of Gilead Sciences by 51.7% during the 1st quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares in the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Gilead Sciences during the 2nd quarter valued at $147,000. Institutional investors own 73.97% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.